1. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
- Author
-
Re D, Seitz-Polski B, Brglez V, Carles M, Graça D, Benzaken S, Liguori S, Zahreddine K, Delforge M, Bailly-Maitre B, Verrière B, Chamorey E, and Barrière J
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, BNT162 Vaccine administration & dosage, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology, Female, Humans, Male, Middle Aged, Multiple Myeloma, SARS-CoV-2 immunology, SARS-CoV-2 physiology, Spike Glycoprotein, Coronavirus immunology, T-Lymphocytes immunology, BNT162 Vaccine immunology, Hematologic Neoplasms, Immunity, Cellular immunology, Immunity, Humoral immunology, Immunization, Secondary methods
- Abstract
Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF